MCM
RGNX icon

Matarin Capital Management’s Regenxbio RGNX Stock Holding History

Matarin Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-133,424
Closed -$7.65M – 279
2019
Q1 		$7.65M Buy
133,424
+43,876
+49% +$2.17M 0.56% 75
2018
Q4 		$3.76M Buy
89,548
+47,312
+112% +$2.78M 0.3% 122
2018
Q3 		$3.19M Buy
+42,236
New +$3.04M 0.21% 154

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Matarin Capital Management's RGNX Position: Q2 2019 in Review

Matarin Capital Management sold out of Regenxbio (RGNX) in Q2 2019, closing a stake of 133,424 shares — an estimated $7.65M sold.

Matarin Capital Management first reported a position in RGNX in Q3 2018 and held it in 3 quarters. The position peaked at $7.65M in Q1 2019. 186 funds tracked by Wall St. Rank hold RGNX as of Q2 2019.

  • Matarin Capital Management reported no remaining Regenxbio position as of Q2 2019 after selling out during the quarter.
  • Matarin Capital Management sold 133,424 Regenxbio shares in Q2 2019, an estimated $7.65M.
  • Matarin Capital Management first reported a position in Regenxbio in Q3 2018 and held it in 3 quarters.
  • Matarin Capital Management's Regenxbio position peaked at $7.65M in Q1 2019.
  • 186 funds tracked by Wall St. Rank held Regenxbio as of Q2 2019.

Based on Matarin Capital Management's 13F filing for Q2 2019, filed 8 Aug 2019.